December 26, 2016: Hearing takeover rumors circulating about OpGen. The rumors are coming from the fact that Merck Global Health Innovation Fund disclosed a huge 37.5% stake in OpGen according to a schedule 13D filing.
November 16, 2016: Rodman & Renshaw/H.C. Wainwright reiterates a Buy rating on OpGen but cuts their price target from $3.25 to $2.50.
November 14, 2016: OpGen collaborates with Merck to develop novel rapid diagnostics and informatics tools to combat antibiotic resistance.
OpGen Stock Chart
OpGen, Inc. is an early commercial-stage company using molecular testing and bioinformatics to assist healthcare providers in combating multi-drug resistant bacterial infections.